Affiliation:
1. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
2. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
3. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Abstract
Objective: To assess the impact of mesorectal excision for upper rectal cancer on long-term treatment results.Materials and methods. 227 patients with upper rectal cancer in the period between January 2004 and December 2014 were analyzed. The study included patients over 18 years of age with upper rectal cancer, stage T2-4N0-2M0. The patients were divided into 2 groups: partial mesorectal excision (PME) and total mesorectal excision (TME).Results. 226 (99.6 %) of 227 patients underwent surgical treatment. PME was performed in 199 (85.4 %) patients, TME in 27 (14.6 %) patients. TME was significantly more often performed in patients with preoperative treatment (р = 0.03). Operative time did not differ significantly between the two groups (TME - 186 minutes and PME - 168 minutes; р = 0.34). Postoperative complications were observed in 12.3 % of cases with no significant differences between the groups (TME - 14.3 %, PME - 12.1 %; р = 0.68). Anastomotic failure was noted in 7.1 % of cases, all in the PME group. Median follow-up was 57 months. The number of deaths was 29 (12.8 %), in the PME group - 27 (13.6 %), and in the TME group - 2 (7.4 %) (р = 0.61). Local recurrences developed in 4 (2.2 %) patients of the PME group and none in TME group. Distant metastases were diagnosed in 2 patients (8 %) of the TME group and 23 patients (12.1 %) of the PME group (р = 0.509). Overall 5-year survival in the TME group was 79.6 %, in the PME group - 86.3 % (р = 0.463), and 5-year disease-free survival was 79.3 % and 86 %, respectively (р = 0.521).Conclusion. Multivariate analysis showed that the volume of mesorectal excision did not affect the rate of disease recurrence and disease-free survival in both groups.
Publisher
Publishing House ABV Press
Reference18 articles.
1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49. DOI: 10.3322/caac.21660.
2. Benson A.B.3rd, Venook A.P., Al-Hawary M.M. et al. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. Featured Updates to the NCCN Guidelines. Vol. 18. Issue 7. Online Publication Date: Jul 2020.
3. ESMO Clinical Practice Guidelines. [Electronic resource]. 2018. Available at: http://www.esmo.org/content/download/30934/621019/file/ESMO-2018-Industry-Guidelines.
4. Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma. 2nd English edn. Tokyo: Kanehara & Co., Ltd, 2009.
5. Tanaka A., Sadahiro S., Suzuki T. et al. A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classication of colorectal carcinoma (JCCRC) and Western guidelines. Surg Today 2017;47(9):1086-93. DOI: 10.1007/s00595-017-1487-9.